|
|
|
World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology
Karen I Barnes, Niklas Lindegardh, Olumide Ogundahunsi, Piero Olliaro, Christopher V Plowe, Milijaona Randrianarivelojosia, Grace O Gbotosho, William M Watkins, Carol H Sibley, Nicholas J White Malaria Journal 2007, 6:122 (6 September 2007)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central
|
Editor’s summary
The determinants of treatment response are multi-factorial, but reaching adequate blood concentrations is pivotal to cure. Pharmacokinetic data can inform on optimal dosing, but only small number of patients have been studied, with even less conducted in the most vulnerable populations. A better understanding of the pharmacokinetic properties of antimalarials and a more clear definition of what constitutes “therapeutic drug levels” would allow more precise use of the term “antimalarial resistance”, as it would indicate when treatment failure is not caused by intrinsic parasite resistance but is the result of inadequate drug levels.
|
|
|
|
World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria
Christopher V Plowe, Cally Roper, John W Barnwell, Christian T Happi, Hema H Joshi, Wilfred Mbacham, Steven R Meshnick, Kefas Mugittu, Inbarani Naidoo, Ric N Price, Robert W Shafer, Carol H Sibley, Colin J Sutherland, Peter A Zimmerman, Philip J Rosenthal Malaria Journal 2007, 6:121 (6 September 2007)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central
|
Editor’s summary
The review describes previous successes on using molecular markers of drug resistance and lessons learned. A standardized global database of molecular markers of drug resistance linking up with databases containing in vivo efficacy trial results, in vitro and pharmacokinetic studies could form an essential resource to guide policy makers in choice of first line antimalarial drugs, drugs for intermittent preventive treatment (IPT) and prophylactic drugs for travellers.
|
|
|
|
World Antimalarial Resistance Network (WARN) II: In vitro antimalarial drug susceptibility
David J Bacon, Ronan Jambou, Thierry Fandeur, Jacques Le Bras, Chansuda Wongsrichanalai, Mark M Fukuda, Pascal Ringwald, Carol Sibley, Dennis E Kyle Malaria Journal 2007, 6:120 (6 September 2007)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central
|
Editor’s summary
The in vitro antimalarial drug susceptibility assay determines ex-vivo growth of parasite in the presence of serial drug concentrations and, thus, measures intrinsic resistance without interfering host effects as drug metabolism and immunity. The aim of the network would be to use standardized methodologies to establish baseline values of sensitivity to commonly used antimalarial agents from key regions of the world
|
|
|
|
World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs
Ric N Price, Grant Dorsey, Elizabeth A Ashley, Karen I Barnes, J Kevin Baird, Umberto d'Alessandro, Philippe J Guerin, Miriam K Laufer, Inbarani Naidoo, François Nosten, Piero Olliaro, Christopher V Plowe, Pascal Ringwald, Carol H Sibley, Kasia Stepniewska, Nicholas J White Malaria Journal 2007, 6:119 (6 September 2007)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central
|
Editor’s summary
Since the late 1970’s efforts have been made by WHO to create a monitoring system for the evaluation of the global development of drug resistance. The complexity of combination antimalarials and the multiplicity of interested parties in this field, now make a much broader and all inclusive monitoring/surveillance system essential.
|
|
|
|
The rationale and plan for creating a World Antimalarial Resistance Network (WARN)
Carol Sibley, Karen I Barnes, Christopher V Plowe Malaria Journal 2007, 6:118 (6 September 2007)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central
|
Editor’s summary
The introduction to a series of four papers which describe plans to establish an international malaria drug resistance network: it sets out the case for such a network and provides the relevant background
|
